TRANSTHERA-B(02617),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02617 TRANSTHERA-B

Trading 02-02 13:21:16

77.400

-5.250

-6.35%

High85.700	Low77.300	Vol1.22M
Open85.700	D1 Closing82.650	Amplitude10.16%
Mkt Cap30.88B	Tradable Cap23.53B	Total Shares399.00M
T/O96.85M	T/O Rate0.40%	Tradable Shares304.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02617","market":"HK","secType":"STK","nameCN":"TRANSTHERA-B","latestPrice":77.4,"timestamp":1770009660111,"preClose":82.65,"halted":0,"volume":1216000,"delay":0,"changeRate":-0.06352087114337568,"floatShares":304000000,"shares":399000000,"eps":-0.8082861437863585,"marketStatus":"Trading","change":-5.25,"latestTime":"02-02 13:21:16","open":85.7,"high":85.7,"low":77.3,"amount":96845300,"amplitude":0.101633,"askPrice":77.5,"askSize":1000,"bidPrice":77.35,"bidSize":11500,"shortable":0,"etf":0,"ttmEps":-0.697303436215984,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1770019800000},"marketStatusCode":2,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":82.65,"openAndCloseTimeList":[[1769995800000,1770004800000],[1770008400000,1770019200000]],"volumeRatio":1.007977,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02617","defaultTab":"news","newsList":[{"id":"2604199317","title":"TransThera Sciences Completes HK$195 Million Share Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2604199317","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604199317?lang=en_us&edition=fundamental","pubTime":"2026-01-20 17:52","pubTimestamp":1768902774,"startTime":"0","endTime":"0","summary":"TransThera Sciences  completed the sale of nearly HK$195 million worth of shares, according to a Hong Kong bourse filing Tuesday.The firm sold 2.1 million shares priced at HK$92.85 apiece to raise funds for the clinical development of its drug candidates.The shares represent 0.69% of the company's issued H shares and 0.53% of its total issued shares following the sale.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02617"],"gpt_icon":0},{"id":"1161211868","title":"TransThera Sciences (Nanjing), Inc. (2617) Completes H Share Placing and Raises Approximately HK$190.14 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1161211868","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161211868?lang=en_us&edition=fundamental","pubTime":"2026-01-20 17:03","pubTimestamp":1768899802,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. (Stock Code: 2617) announced the completion of a placing of 2,100,000 new H shares under its general mandate. Placing shares were priced at HK$92.85 each,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"gpt_icon":0},{"id":"2604193755","title":"Transthera Sciences Completes Placement of New H Shares Under General Mandate","url":"https://stock-news.laohu8.com/highlight/detail?id=2604193755","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604193755?lang=en_us&edition=fundamental","pubTime":"2026-01-20 16:56","pubTimestamp":1768899367,"startTime":"0","endTime":"0","summary":"Transthera Sciences Completes Placement of New H Shares Under General Mandate               Transthera Sciences (Nanjing) Inc. has announced the completion of its placing of new H shares under the...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL5svB8T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"gpt_icon":0},{"id":"1142097731","title":"Hong Kong Stock Alert | TRANSTHERA-B (02617) Falls Over 10% Again, Plans Share Placement to Raise Net HKD 1.9 Billion Primarily for Core Product R&D","url":"https://stock-news.laohu8.com/highlight/detail?id=1142097731","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142097731?lang=en_us&edition=fundamental","pubTime":"2026-01-20 11:27","pubTimestamp":1768879642,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) dropped more than 10% again. As of the time of writing, the stock was down 9.02%, trading at HKD 84.7, with a turnover of HKD 117 million. The company previously announced its...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"gpt_icon":0},{"id":"2603665557","title":"Transthera Sciences (Nanjing) Inc - to Place 2.1 Mln Shares at HK$92.85 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2603665557","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603665557?lang=en_us&edition=fundamental","pubTime":"2026-01-14 06:31","pubTimestamp":1768343509,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nFWN3YE11S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02617"],"gpt_icon":0},{"id":"2603565550","title":"Transthera Sciences Announces HK$195 Million Private Placement of New H Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2603565550","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603565550?lang=en_us&edition=fundamental","pubTime":"2026-01-14 06:30","pubTimestamp":1768343454,"startTime":"0","endTime":"0","summary":"Transthera Sciences  Inc. has announced a private placement of new H shares under a general mandate. According to the company, a total of 2,100,000 H shares will be placed at a price of HK$92.85 per share through a sole placing agent on a best effort basis. The placement represents approximately 0.70% of the company’s issued shares. The new shares will not be registered under the United States Securities Act of 1933 and will not be offered or sold in the United States. The company does not intend to conduct a public offering of these securities in the US.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDLc7dCvj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"gpt_icon":0},{"id":"1111791023","title":"TRANSTHERA-B (02617) Announces Clinical Data for Tienigotinib Monotherapy in Advanced Cholangiocarcinoma Patients at 2026 ASCO GI Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=1111791023","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111791023?lang=en_us&edition=fundamental","pubTime":"2026-01-12 07:14","pubTimestamp":1768173258,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) announced that the company presented clinical data for its core product, Tienigotinib, as a monotherapy for patients with advanced cholangiocarcinoma (CCA) in a poster session at...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"gpt_icon":0},{"id":"2602256317","title":"Transthera Sciences Unveils Promising Phase II Data for Tinengotinib in Advanced Cholangiocarcinoma at ASCO GI 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602256317","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602256317?lang=en_us&edition=fundamental","pubTime":"2026-01-12 07:00","pubTimestamp":1768172438,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on January 11, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nNDL3hPf7T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"gpt_icon":0},{"id":"1123551011","title":"Year-End Arrives, Still No Explanation for TRANSTHERA-B's Index Inclusion","url":"https://stock-news.laohu8.com/highlight/detail?id=1123551011","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123551011?lang=en_us&edition=fundamental","pubTime":"2025-12-30 17:00","pubTimestamp":1767085230,"startTime":"0","endTime":"0","summary":"It has already been two or three months since the incident occurred, yet Shenzhen Securities Information Co., Ltd. still has not issued any explanation regarding the matter of TRANSTHERA-B's...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"gpt_icon":0},{"id":"2592131490","title":"BUZZ-HK-listed TransThera climbs on new drug application","url":"https://stock-news.laohu8.com/highlight/detail?id=2592131490","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592131490?lang=en_us&edition=fundamental","pubTime":"2025-12-19 10:47","pubTimestamp":1766112441,"startTime":"0","endTime":"0","summary":"BUZZ-HK-listed TransThera climbs on new drug application ** Shares of therapy developer for oncology, inflammatory and cardiometabolic diseases TransThera Sciences  Inc 2617.HK climb 3% to HK$173    ** Stock on course to end the week up 5.9%, snapping three straight weekly losess** TransThera said new drug application for its Tinengotinib tablets for treatment of metastatic cholangiocarcinoma in adults has been accepted by the Center for Drug Evaluation of China's National Medical Products Administration ** There is no assurance that the relevant product will ultimately be successfully developed and marketed - Co** Stock, which debuted on June 23, up 1,190% so far from the offer price of HK$13.15 apiece** YTD, Hang Seng Biotech index .HSBIO up 74.3%  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nL1N3XP02I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"gpt_icon":0},{"id":"2592136484","title":"New Drug Application for Tinengotinib Tablets Accepted by the National Medical Products Administration","url":"https://stock-news.laohu8.com/highlight/detail?id=2592136484","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592136484?lang=en_us&edition=fundamental","pubTime":"2025-12-19 09:47","pubTimestamp":1766108828,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nTUA5ZSDYG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02617","BK1161"],"gpt_icon":0},{"id":"1146650124","title":"TRANSTHERA-B (02617): New Drug Application for Tinengotinib Tablets Accepted by China's NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=1146650124","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146650124?lang=en_us&edition=fundamental","pubTime":"2025-12-19 08:24","pubTimestamp":1766103876,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) announced that the new drug application for Tinengotinib Tablets has been accepted by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"gpt_icon":0},{"id":"2592389831","title":"China's NMPA Accepts New Drug Application for Transthera Sciences' Tinengotinib Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2592389831","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592389831?lang=en_us&edition=fundamental","pubTime":"2025-12-19 08:12","pubTimestamp":1766103161,"startTime":"0","endTime":"0","summary":"TransThera Sciences  Inc. announced that its new drug application for Tinengotinib tablets has been accepted by the Center for Drug Evaluation of the National Medical Products Administration in China. The application pertains to the treatment of adults with unresectable advanced or metastatic cholangiocarcinoma who have received at least one prior systemic treatment and FGFR inhibitor treatment. Tinengotinib tablets have previously been included in lists for priority review and breakthrough therapy designation for this indication.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL2CjDmC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"gpt_icon":0},{"id":"2592138679","title":"Transthera Sciences (Nanjing) Inc - Nmpa Accepts New Drug Application for Tinengotinib Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2592138679","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592138679?lang=en_us&edition=fundamental","pubTime":"2025-12-19 08:11","pubTimestamp":1766103111,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nFWN3XO16A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02617","BK1161"],"gpt_icon":0},{"id":"1103397138","title":"TRANSTHERA-B (02617) Announces Exploratory Phase 2 Clinical Results of Core Product Tinengotinib for Cholangiocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1103397138","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103397138?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:08","pubTimestamp":1765973296,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) announced that the exploratory Phase 2 clinical results of its core product, tinengotinib, for cholangiocarcinoma conducted in the U.S. were recently published in *The Lancet...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"gpt_icon":0},{"id":"2592994290","title":"Transthera Sciences Reports Positive Phase 2 Results for Tinengotinib in Cholangiocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2592994290","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592994290?lang=en_us&edition=fundamental","pubTime":"2025-12-17 19:55","pubTimestamp":1765972506,"startTime":"0","endTime":"0","summary":"TransThera Sciences  Inc. has announced the publication of clinical results from a US-based Phase 2 trial evaluating its core product, Tinengotinib, in patients with cholangiocarcinoma . The results were published in The Lancet Gastroenterology and Hepatology. The study involved patients with FGFR2 fusion-positive CCA who had either primary or acquired resistance to prior FGFR inhibitor therapy, as well as patients with other FGFR alterations or FGFR wild-type tumors. Tinengotinib demonstrated clinical activity in patients with FGFR2 fusion-positive CCA with acquired resistance to FGFR inhibitors, as well as in other FGFR-altered subtypes. The company notes there is no assurance that Tinengotinib will ultimately be successfully developed and marketed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shoul","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL7klhrb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"gpt_icon":0},{"id":"1189029586","title":"HK Movers | HK's Biotech Shares Soar. TransThera up 19%; JOINN up 11%; Xuanzhu Bio up 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1189029586","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189029586?lang=en_us&edition=fundamental","pubTime":"2025-12-17 11:43","pubTimestamp":1765943020,"startTime":"0","endTime":"0","summary":"Hong Kong’s biotech stocks rose on Wednesday.TransThera rose 19%; JOINN rose 11%; Xuanzhu Bio up 6%; Remegen, Wuxi Bio up 2%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"56cee07d353081b3259b34f98f1a012b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","02575","06127"],"gpt_icon":0},{"id":"1121164453","title":"HK Stock Movement | TRANSTHERA-B (02617) Surges Nearly 14% After Announcing Positive Clinical Results for Tinengotinib in The Lancet Sub-Journal","url":"https://stock-news.laohu8.com/highlight/detail?id=1121164453","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121164453?lang=en_us&edition=fundamental","pubTime":"2025-12-17 10:38","pubTimestamp":1765939096,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) surged nearly 14%, rising 13.85% to HKD 166.1 by the time of writing, with a trading volume of HKD 112 million. The company recently announced that the exploratory Phase 2...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"gpt_icon":0},{"id":"2589868705","title":"TransThera Sciences Reports Positive Phase 2 Results for Tinengotinib in Cholangiocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2589868705","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589868705?lang=en_us&edition=fundamental","pubTime":"2025-12-05 12:32","pubTimestamp":1764909130,"startTime":"0","endTime":"0","summary":"TransThera Sciences  Inc. has announced the publication of clinical results from a US-based Phase 2 trial evaluating tinengotinib  in patients with cholangiocarcinoma . The findings have been published in The Lancet Gastroenterology and Hepatology. The multicenter, open-label Phase 2 trial enrolled patients with FGFR2 fusion-positive CCA who had demonstrated resistance to prior FGFR inhibitor therapy, as well as patients with other FGFR alterations and FGFR wild-type tumors. Tinengotinib demonstrated clinical activity, including durable responses and meaningful clinical benefit, in patients with FGFR2 fusion-positive CCA with acquired resistance to FGFR inhibitors, as well as in other FGFR-altered subtypes. The results support further clinical investigation in a Phase 3 registration study.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is fo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL9BLJHK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"gpt_icon":0},{"id":"2589865231","title":"TransThera Sciences (Nanjing) (SEHK:2617): Assessing a Lofty Valuation After a 200% Three-Month Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=2589865231","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589865231?lang=en_us&edition=fundamental","pubTime":"2025-12-05 10:23","pubTimestamp":1764901415,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing) SEHK:2617 has quietly delivered a sharp move over the past 3 months, climbing more than 200%, which naturally raises the question of what the market is now pricing in.\nSee our latest analysis for TransThera Sciences (Nanjing).\nThat surge sits on top of an already extraordinary year to date, with a 726.38% year to date share price return. This suggests investors are rapidly repricing TransThera’s risk and growth prospects, even as near term swings remain...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2617/transthera-sciences-nanjing-shares/news/transthera-sciences-nanjing-sehk2617-assessing-a-lofty-valua","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2617/transthera-sciences-nanjing-shares/news/transthera-sciences-nanjing-sehk2617-assessing-a-lofty-valua","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02617","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.transtherabio.com","stockEarnings":[{"period":"1week","weight":-0.0102},{"period":"1month","weight":-0.2807},{"period":"3month","weight":-0.5503},{"period":"6month","weight":1.1495},{"period":"1year","weight":5.2852},{"period":"ytd","weight":-0.2807}],"compareEarnings":[{"period":"1week","weight":0.0238},{"period":"1month","weight":0.0685},{"period":"3month","weight":0.0571},{"period":"6month","weight":0.1175},{"period":"1year","weight":0.3541},{"period":"ytd","weight":0.0685}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"TransThera Sciences (Nanjing) Inc is a China-based biopharmaceutical company principally focusing on discovering and developing innovative small molecule therapies for oncology, inflammatory and cardiometabolic diseases. The Company's core product Tinengotinib is a registrational clinical stage, internally discovered and developed, MTK inhibitor indicated for certain relapsed or refractory, drug-resistant solid tumors. The Company's oncology pipeline includes TT-00973 (against AXL), TT-01488 (for hematologic malignancies), TT-01688 (for inflammatory diseases) and TT-00920 (for chronic heart failure). The products are capable of being efficacious in a broad range of cancer types (including prostate cancer, HCC, breast cancer, and BTC). It is also applied to cure hepatocellular carcinoma, breast cancer, biliary tract cancer and Pan-FGFR solid tumor.","exchange":"SEHK","name":"TRANSTHERA-B","nameEN":"TRANSTHERA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"TRANSTHERA-B(02617),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest TRANSTHERA-B(02617) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"TRANSTHERA-B,02617,TRANSTHERA-B股票,TRANSTHERA-B股票老虎,TRANSTHERA-B股票老虎国际,TRANSTHERA-B行情,TRANSTHERA-B股票行情,TRANSTHERA-B股价,TRANSTHERA-B股市,TRANSTHERA-B股票价格,TRANSTHERA-B股票交易,TRANSTHERA-B股票购买,TRANSTHERA-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"TRANSTHERA-B(02617),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest TRANSTHERA-B(02617) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}